



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁴ : C07C 93/14, C07D 295/08 C07D 295/18, 211/58, 401/04 C07C 97/10 // (C07D 401/04 C07D 235:25, 211:58, 401:04 C07D 235:08, 211:58)</p>	A1	<p>(11) International Publication Number: WO 87/ 02035</p> <p>(43) International Publication Date: 9 April 1987 (09.04.87)</p>
<p>(21) International Application Number: PCT/EP86/00606</p> <p>(22) International Filing Date: 29 September 1986 (29.09.86)</p> <p>(31) Priority Application Numbers: 8524491 8615560</p> <p>(32) Priority Dates: 4 October 1985 (04.10.85) 25 June 1986 (25.06.86)</p> <p>(33) Priority Country: GB</p> <p>(71) Applicant (for all designated States except US): MAG- GIONI-WINTHROP S.P.A. [IT/IT]; Via Giuseppe Colombo, 40, I-20133 Milano (IT).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only) : PICCIOLA, Giam- paolo [IT/IT]; Piazzale Baracca, 6, I-20123 Milano (IT). RIVA, Mario [IT/IT]; Via Monteverdi, 21, I- 20052 Monza (IT). RAVENNA, Franco [IT/IT]; Via Vincenzo Monti, 57-A, I-20145 Milano (IT). GENTI- LI, Piergiorgio [IT/IT]; Via Mazzini, 30, I-24047 Tre- viglio (IT).</p>	<p>(74) Agent: BELLENGHI, Mario; A. Giambrocono & C. S.R.L., Via Rosolino Pilo, 19/B, I-20129 Milano (IT).</p> <p>(81) Designated States: AT (European patent), AU, BB, BE (European patent), BG, BR, CF (OAPI patent), CG (OAPI patent), CH (European patent), CM (OAPI patent), DE (European patent), DK, FI, FR (Euro- pean patent), GA (OAPI patent), GB (European pa- tent), HU, IT (European patent), JP, KP, KR, LK, LU (European patent), MC, MG, ML (OAPI patent), MR (OAPI patent), MW, NL (European patent), NO, RO, SD, SE (European patent), SN (OAPI patent), SU, TD (OAPI patent), TG (OAPI patent), US.</p> <p>Published With international search report. With amended claims and statement.</p>	
<p>(54) Title: FUSED CYCLOALIPHATIC AMINOALCOHOLS</p> <div style="text-align: center; margin: 20px 0;"> <p>(1)</p> </div> <p>(57) Abstract</p> <p>Fused cycloaliphatic aminoalcohols having pharmacological activity as anti-hypertensive, platelet aggregation inhi- biting, hypolipemic, antianoxic and spasmolytic activity. The compounds have the generic formula (I), in which the sym- bol n is an integer selected from 1 and 2, the compounds pertaining therefore to the indanol and tetralol series.</p>		

FOR THE PURPOSES OF INFORMATION ONLY


Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	ML	Mali
AU	Australia	GA	Gabon	MR	Mauritania
BB	Barbados	GB	United Kingdom	MW	Malawi
BE	Belgium	HU	Hungary	NL	Netherlands
BG	Bulgaria	IT	Italy	NO	Norway
BJ	Benin	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland				

FUSED CYCLOALIPHATIC AMINOALCOHOLS

DESCRIPTION

This invention is concerned with new pharmacologically active compounds. More particularly, the compounds with which this invention is concerned are fused cycloaliphatic aminoalcohols of the formula:




wherein n represents an integer selected from 1 and 2;

R , R_1 and R_2 represent hydrogen or a lower alkoxy group, with the proviso that at least two alkoxy groups are present, or two adjacent radicals selected from $R+R_1$ and R_1+R_2 represent an alkylenedioxy group,


R_3 represents hydrogen and R_4 represents an alkyl group; or alternatively R_3 and R_4 taken together represent a divalent group selected from

a)




wherein Y represent hydrogen or halogen;

b)




wherein A is a group selected from




R_4 represents a lower alkyl group;

c)



and

d)



wherein W represents hydrogen, phenyl, alkoxyphenyl, methylphenyl, 2-furoyl, nicotinoyl radical or a radical




in which Z represents 2-thienyl or phenyl optionally substituted with 1-3 halogen or alkoxy groups: and their salts with inorganic acids, organic acids, cationic exchange resins and complexes with cyclodextrins.

As apparent to all those skilled in organic chemistry, the compounds, having two structural asymmetry centers, may exist both in the cis and trans configuration.

In most cases, by the manufacturing process which will be hereinafter described, a mixture of the two steric isomers is obtained, and an appropriate separation may occasionally be necessary. In other instances, however, formation of one single isomer is so prevailing as to approach 100 per cent, and a


separation is not required unless the product is desired in an analytically pure condition for purposes of study.

The configuration of the cis and trans isomers of the structure



was assigned through ^1H NMR (Nuclear Magnetic Resonance) spectra by determining the characteristic coupling constants ($J_{\text{C-1,C-2}}$) of several compounds. Said spectra show $\text{C}_1\text{-H}$ as doublet with $J = 9.7 - 10.23$ Hz in the trans derivatives and $J = 2.5 - 3.5$ in the cis derivatives.

In the series of compounds of the structure




the configuration was assigned using the NOE (Nuclear Overhauser Effect). (J.H. Noggle and R.E. Schirmer, the Nuclear Overhauser Effect, Academic Press, London, 1971). Actually, the simple determination of the coupling constants through ^1H NMR is not indicative, the differences between them being very small.

In addition to the NOE, the cis-trans configuration was also confirmed using the IR spectroscopy (H.J. Rimek et al. Liebigs Ann. Chem. 726, 25-29, 1969). The spectra of the individual isomers were registered at different concentrations using methylene dichloride as the solvent. It is well known that only the cis series forms

intramolecular hydrogen bonds. In the present instance, therefore, the intensity ratio between the free hydroxyl band and that of the bound hydroxyl remains constant by progressive dilution, while in the trans series that ratio markedly changes in favor of the free hydroxyl band.

The chemical process for the preparation of the invention compounds consists in contacting a bromo ketone of the partial formula IV with a secondary amine to give the amino ketone of the partial formula V.

The amino ketone is then hydrogenated to give the desired amino alcohol



Depending on the circumstances, the amino ketone V may be isolated from the reaction mixture before it is hydrogenated. On the other hand, if the intermediate V show a low degree of stability, it is preferable to hydrogenate it directly in the reaction mixture in which it is formed by reaction of the bromo ketone with the secondary amine.

The first step of the process is carried out in the presence of a proton acceptor, such as an alkali metal or earth alkali carbonate or bicarbonate or a tertiary amine.

In some instances, an excess over the molecular amount of the same secondary amine which is being contacted with the bromo ketone may be used with satisfactory results. Usually this first step is carried out in an inert solvent such as a lower alkanol, for

instance methanol or ethanol, or a ketone, such as a di-lower alkyl ketone, for instance acetone or methyl ethyl ketone. It is immaterial whether the amine is added to the bromo ketone, both or only one of them being dissolved in the solvent, or vice versa the bromo ketone is added to the amine, still both in solution or only one of them. The appropriate way of conducting the first step will be selected considering the properties of the reactants and their reactivity. The reaction temperature is also adjusted depending of the reactivity of the two reactants, although normally the boiling temperature of the solvent is generally preferred.


The second step of the process, i.e. the hydrogenation, may be carried out by any conventional hydrogenation procedure apt to convert a keto into a hydroxy group; However, we have found that the hydrogenation is best performed by using a metal hydride, preferably a double hydride, such as NaBH_4 , LiAlH_4 etc., by conventional procedures in a solvent inert to the hydrogenation reaction, which in the case of NaBH_4 may be water, or a lower alkanol, such as methanol or ethanol, both in the presence of various amounts of water or under anhydrous condition; or alternatively, when for instance LiAlH_4 is used, the solvent may be diethyl ether, tetrahydrofuran and the like, at a temperature which may range from 0-5°C to the boiling temperature of the selected solvent.

When the intermediate is not isolated from the reaction mixture of the first reaction step, and depending on the nature of the selected hydrogenating agent, this may added directly to the intermediate reaction mixture either in the form of a solution in an appropriate solvent not interfering with the hydrogenation, and the solution of the hydrogenating agent is added while maintaining the mixture at the reflux temperature or at a lower temperature

which may be found more convenient depending on the observed reaction rate; or the hydrogenating agent may be added at portions or by dropping its solution in an appropriate solvent while maintaining the reaction mixture at 0-5°C until the addition is complete, then heating the mixture to reflux until the reaction is complete.

Obviously the skilled chemist will select the procedure appropriate to the nature of the hydrogenating agent and the substrate and the reactant used.

An alternative process for preparing the invention compounds consists in reacting an amino alcohol of the partial formula VI with an aldehyde of the partial formula VII at a temperature between about 0°C and 20°C in a solvent, preferably in a lower alkanol such



as methanol or ethanol, while adding at portions to the reaction mixture a hydrogenating agent preferably selected from metal hydrides or double hydrides or double cyano hydrides, such as sodium boron cyano hydride or lithium boron cyano hydride, these latter hydrogenating agents being preferred.

When the addition of the hydrogenation agent is terminated, the mixture is allowed to arrive slowly to the room temperature in order to complete the reaction.

It is apparent to those having knowledge of organic chemistry that the last described method of preparation is convenient when the

symbol X in the partial formula VII above represents a linear or branched alkyl radical.

Alternatively, the hydrogenation may be carried out by using conventional procedures such as hydrogen in the presence of a catalyst.

The compounds of this invention show anti-hypertensive, platelet aggregation inhibiting, hypolipemic, antianoxic, spasmolytic, anti-thrombotic and Ca^{++} antagonizing activity.

The anti-hypertensive activity was tested on groups of 5 SH rats (spontaneously hypertensive rats) and 5 DOCA rats (deoxycorticosterone acetate and sodium chloride loaded rats) weighing $200 \pm 10\text{g}$, fasting from 18 hrs and treated orally with the invention compounds suspended in 0.5% gum arabic.

Changes in blood pressure (mm Hg) before ($T=0$) and after treatment (2, 4 and 6 hrs) were measured according to the method of tail artery plethysmography reported in "Spontaneously hypertensive rats (SHR), guidelines for breeding, care and use", SHR Conference, 1976, page 11.

The heart rate was also tested (BP Recorder No. 8006 supplied by Basile, Comerio, Italy). The arterial pressure before the treatment was 210 ± 10 mmHg in SHR and 200 ± 10 in DOCA rats.

Table 1 shows that the tested compounds are endowed with good anti-hypertensive activity.

The peak effect was noted 2-4 hrs after the treatment and the duration of the effect was more than 6 hrs: in this period no

remarkable increase of heart rate was registered. Some of the compounds were tested on SH rats at the dosis of 1 and/or 5 mg/kg and their activity appeared to be dosis-dependant. For instance, administration of 5 mg/kg p.o. of MG 28401, M 28427 and MG 38007 causes a pressure decrease of 37.6, 26.2 and 20 mm Hg respectively. Administration of 1 mg/kg p.o. of MG 28427 causes a pressure decrease of 17.4 mm Hg.

Under the same conditions Tibalosine was poorly active at the dosis of 5 mg/kg p.o. (pressure decrease 13 mm Hg).

TABLE 1

Compound	Max. changes in systolic pressure (mmHg) Dose tested = 15 mg/kg po	
	SHR	DOCA rats
MG 38005	- 42	- 27
MG 38007	- 61.4	- 37.4
MG 38019	- 56	- 23
MG 28401	- 67	- 40.2
MG 28427	- 47	- 41.2
MG 38060	- 47	- 25.5
MG 38112	- 35	- 19
MG 38122	- 41.9	- 28
Tibalosine	- 67.0	-
Urapidil	- 72.4	-

To test the antagonism against phenylephrine (PHE) induced hypertension, male rats CrI:CD (SD)BR were anesthetized with urethane, 1 g/kg i.p.

PHE was administered cumulatively and dose-response curves were obtained (controls). Dose-response curves were similarly obtained after administration of the test drugs (1 mg/kg i.v.). From the two curves the PHE dosis causing a 50 mm Hg increase of the arterial pressure was calculated. The PHE dosis was about 3 times, in comparison with the controls, after administration of MG 28401 and MG 28427, and about 9 times after MG 38007, MG 38060 and 38041.

The protection against toxic adrenaline doses was tested as follows. Groups of 10-20 male mice CrI:CD 1(CR) BR were treated orally with carrier (controls) and with various doses of the compounds. After 2 hrs 14.5 mg/kg of 1-adrenaline was administered intraperitoneally and mortality was recorded after 24 hrs; in controls mortality was 100%. From log-dose-% protection curves the 50% protective doses were calculated (Litchfield et al., J. Pharmacol. Exp. Ther. 96, 99, 1949).

Table 2 gives the results obtained with some of the compounds as compared with known drugs.

TABLE 2

Compound	DP ₅₀ mg/kg po	Conf. limits (P = 0.05)
MG 38007	10.0	7.6 - 13.1
MG 28401	3.5	2.47 - 4.96
MG 38028	0.73	0.47 - 1.12
MG 38041	0.31	0.21 - 0.46
MG 38060	1.28	0.99 - 1.65
MG 38100	8.5	6.07 - 11.9
MG 38112	4.4	3.4 - 5.7
MG 38107	2.45	1.79 - 3.34
MG 38119	4.4	3.31 - 5.84
MG 38121	2.75	2.25 - 3.35
MG 16456	1.85	1.39 - 2.85
Prazosin	0.70	0.59 - 0.83
Tibalosine	5.5	3.36 - 8.99
Phentolamine	8.0	6.3 - 10.15

The receptor binding assay for the inhibition of ^3H -Prazosin, ^3H -clonidine and ^3H -spiperone binding to rat brain membrane was carried out according to Greenberg et al., Life Sci. 19, 69, 1976, and U'Prichard et al., Molec. Pharmacol. 13, 454, 1977.

Data for the tested compounds are reported in Table 3 where the 50% inhibiting concentrations (IC_{50}) of Tibalosine and Urapidil are also given. The invention compounds show a good affinity toward α_1 -adrenergic receptors, comparable with or higher than the two comparison substances, and poor or no affinity toward α_2 -adrenergic receptors.

A moderate affinity toward serotonergic 2 (5-HT_2) receptors is displayed by MG 38007 MG 28401.

TABLE 3

Compound	Concentration (M)	% Inhibition of the specific binding		
		³ H-Prazosin (χ_1)	³ H-Clonidine (χ_2)	³ H-Spiperone (5-HT ₂)
MG 38007	5.4×10^{-7}	75	3.5	49
	5.4×10^{-6}	96	32.5	93
MG 38019	5.4×10^{-7}	35.5	0	10
	5.4×10^{-6}	82	6.7	33
MG 28401	5.4×10^{-7}	54.5	0	41
	5.4×10^{-6}	92	0	81
Tibalosine	IC ₅₀ (a)	4×10^{-7}	1×10^{-3}	-
Urapidil	IC ₅₀ (b)	8×10^{-7}	1.4×10^{-5}	-

(a) Van Zwieten P.A. et al. - Arch. int. Pharmacodyn. 266, 254; 1983

(b) van Zwieten P.A. et al. - Arch. int. Pharmacodyn. 276, 189; 1985

BAD ORIGINAL

The effect on platelet aggregation was tested ex vivo according to the method of Minsker, (J. Pharmacol. Exp. Ther. 210, 37, 1979) slightly modified. Groups of 3 rats (280-350 g) were treated orally with vehicle (controls) and compounds (0.15 mM/kg). Blood was collected and pooled from rats of each group 1 hr after treatment and the platelet rich plasma (PRP) was separated by centrifugation.

Platelet aggregation was stimulated with collagen (2-4-mcg/ml) added simultaneously to PRP of control and treated rats. The results were assessed photometrically. Each test was replicated 4 times in groups of 3 animals. Aggregation curves were evaluated in terms of two parameters namely maximum optical density variation (maximum aggregation) and aggregation rate.

Table 4 gives the effects recorded after treatment with some of the tested compounds. They show an activity comparable to Ticlopidine and Suloctidil and only slightly lower than Dipyridamol.

T A B L E 4

Compound	% inhibition	
	Maximum aggregation	Aggregation rate
MG 38007	78.9	80.0
MG 28414	54.0	58.0
MG 28427	64.3	68.8
Ticlopidine	70.0	56.0
Sulfinpyrazone	92.5	89.0
Suloctidil	69.0	57.5

Sprague Dawley Nos male rats (180-200 g) were treated orally for 4 consecutive days with vehicle (0.5 ml/100 g gum arabic 2.5%, controls) and with 1-2 doses of the tested compounds, and were sacrificed at the 5th day after 18 hrs. fasting. Total cholesterol (CHOL), triglycerides (TG), HDL cholesterol (CHOL-HDL) were assayed in serum and the liver was weighed.

Table 5 gives the obtained results. MG 38112 and MG 38107 cause a marked decrease both of CHOL and TG while MG 38041, MG 38128 and MG 38131 decrease TG and increase CHOL-HDL.

The liver weight is not affected. The effect of MG 38112 and MG 38107 is higher than with Clofibrate which, as known, causes a significant liver increase, The Probucol activity is moderate and is noted only after prolonged treatment (8 days).

TABLE 5

Compound	Dose mM/kg po	Normolipemic rats % difference from control			
		CHOL	TG	CHOL-HDL	Liver weight
MG 38041	0.370 x 4 days	~ 0	- 44.2	+ 53.1	+ 2.0
MG 38112	0.185 x 4 days	- 45.2	- 41.8	- 18.6	0
"	0.370 x 4 days	- 52.7	- 58.9	- 21.4	+ 3.9
MG 38107	0.185 x 4 days	- 35.7	- 50.9	- 8.5	+ 5.6
"	0.370 x 4 days	- 30.7	- 58.5	- 26.3	- 0
MG 38128	0.370 x 4 days	~ 0	- 38.8	+ 46.8	+ 8.6
MG 38131	0.370 x 4 days	~ 0	- 41.4	+ 57.2	+ 6.9
Clofibrate	0.820 x 4 days	- 15.0	- 40.0	0	+ 19.5
Probucol	0.205 x 8 days	- 25.0	- 28.0	- 26	+ 4
"	0.820 x 4 days	~ 0	~ 0	+ 18.5	~ 0

The anti-hypoxic activity was determined according to Yasuda et al., Arch. Int. Pharmacodyn. 233, 136, 1978.

Groups of 10 male mice (21-23 g) were treated orally with vehicle (controls) and the invention compounds. After 45 or 90 minutes the animals were decapitated and the gasping time was determined. Table 6 gives the results obtained after administration of some of the invention compounds which display an activity higher than Suloctidil.

TABLE 6

Compound	Dose mg/kg p.o.	Pretreatment time (min.)	Gasping time % diff. from control
MG 38404	100	45	+ 31.0
MG 38041	100	45	+ 56.2
MG 28400	100	45	+ 53.8
MG 38006	100	45	+ 33.2
MG 38100	100	45	+ 95.7
MG 16456	100	90	+ 36.3
Flunarizine	50	90	+ 68.7
Suloctidil	100	45	+ 27.5
Suloctidil	100	90	+ 11.7

The oral acute toxicity in male mice of the invention compound is very low. Thus, for example, the LD_{50} is higher than 500 mg/kg for MG 38041, MG 28400 and MG 38100, higher than 1,000 mg/kg for MG 38019, MG 38006, MG 38112 and MG 38107; and higher than 2,000 mg/kg for MG 38005, MG 28401, MG-28414 and MG 28427.

EXAMPLE 1

cis and trans 2-[4-(2-Oxo-1-benzimidazoliny)-1-piperidinyl]-5,6-dimethoxy-1-indanol (MG 28401 and MG 28427).

A mixture of 3 g of 2-bromo-5,6-dimethoxy-1-indanone (Barltrop, J. Chem. Soc. 1946 958-965) (11 mmole), 2.17 g of 4-(2-oxo-1-benzimidazoliny)-piperidine (10 mmole), 0.92 g of $NaHCO_3$ (11 mmole) in 60 ml of methanol is refluxed with stirring for 16 hours. The mixture is concentrated under reduced pressure, the residue is treated with ethyl acetate, the organic phase is washed with water, dried over sodium sulfate and evaporated under reduced pressure. Yield 3.1 g (76%) of 2-/4-(2-oxo-1-benzimidazoliny)-1-piperidinyl/-5,6-dimethoxy-1-indanone, m.p. 240-242°C (dec.).

Analysis for $C_{23}H_{25}N_3O_4$ % calc. C 67.79 H 6.18 N 10.31
found 67.65 6.17 10.29

To 11.7 g (28.7 mmole) of the foregoing compound, dissolved in 600 ml of anhydrous tetrahydrofuran (THF), 2.18 g of $LiAlH_4$ (57 mmole) are added gradually with stirring at 20°C under a nitrogen atmosphere, then the mixture is allowed to stand under stirring for 2 hours. After cooling to 0°C the excess $LiAlH_4$ is treated with ethyl acetate and then with water.

The formed salts are filtered off and the solution is concentrated under reduced pressure. The obtained crude product is purified by flash chromatography through a column filled with silicagel 60 Merck 230-400 mesh and elution with a $CHCl_3:CH_3OH$ 95:5 mixture.

Yield 2.6 g (22%) of cis-isomer, m.p. 264-266°C after washing with hot ethanol-diethyl ether mixture; and 4.7 g (40%) of trans-isomer, m.p. 245-247°C, after washing as above.

Analysis for $C_{23}H_{27}N_3O_4$	% calc.	C 67.45	H 6.64	N 10.25
<u>cis</u> -isomer found		67.31	6.63	10.24
<u>trans</u> -isomer		67.40	6.66	10.24

The 1H NMR analysis (300 MHz, Py d5) confirmed the cis resp. trans structure of the two isomers.

EXAMPLE 2

cis and trans 2-[4-(1-Oxo-3-phenyl-2-propenyl)-1-piperazinyl]-5,6-dimethoxy-1-indanol (MG 28404 and MG 28414).

A mixture of 3 g of 2-bromo-5,6-dimethoxy-1-indanone (11 mmole), 2.16 g of 1-cinnamoylpiperazine (10 mmole), 0.9 g of sodium bicarbonate (11 mmole) in 9 ml of methanol is refluxed with stirring for 16 hours. Then into the boiling mixture 0.77 g of $NaBH_4$ (20 mmole) dissolved in 1.5 ml of water is dropped and the boiling temperature is maintained for another 4 hours.

The mixture is then cooled causing separation of a precipitate which is collected and washed with water.

On crystallization from ethanol 1.47 g of cis-isomer are obtained (yield 36%); m.p. 204-206°C.

The filtered mother liquor from the reaction mixture is made acidic with aqueous 15% HCl and concentrated under reduced pressure. The residue is made alkaline by addition of an aqueous 5% sodium carbonate solution and extracted with methylene dichloride.

The organic phase is washed with water until neutral and dried over sodium sulfate. The residue which is obtained by evaporation of the solvent under reduced pressure is crystallized from acetone. 1.22 g of trans-isomer are obtained (yield 30%); m.p. 168-170°C.

Analysis for $C_{24}H_{28}N_2O_4$	% calc.	C 70.48	H 6.90	N 6.85
<u>cis</u> -isomer	found	70.34	6.89	6.83
<u>trans</u> - isomer		70.40	6.86	6.80

EXAMPLE 3

trans 5,6-Dimethoxy-2-(n-octylamino)-1-indanol (MG 28400)

To a mixture of 2.5 g of 2-amino-5,6-dimethoxy-1-indanol hydrochloride (10.2 mmole) (R. Perrone et al., *il Farmaco*, Ed. Sci., **39** 255-264, 1984), 1.44 g of octanal (11.2 mmole) and 100 ml of methanol, 2.5 g of sodium cyanoborohydride (39.8 mmole) is added gradually with stirring at 5°C. The mixture is then allowed to stand at room temperature overnight with stirring, then the mixture is made acidic by the addition of dilute HCl while cooling at 5°C, then sodium bicarbonate is added to alkaline reaction and the mixture is extracted with chloroform. The organic phase is dried over sodium sulfate and concentrated under reduced pressure. The crude residue is purified by crystallization from acetone/hexane. Yield 1.5 g (45.7%); m.p. 133-135°C.

Analysis for $C_{11}H_{16}ClNO_3$	% calc.	C 53.77	H 6.56	N 5.70
	found	53.61	6.54	5.68

EXAMPLE 4

cis and trans 2-[4-(1-Oxo-3-phenyl-2-propenyl)-1-piperazinyl]-4,5,6-trimethoxy-1-indanol (MG 38004 and MG 38015).

A mixture of 3.3 g (11 mmole) of 2-bromo-4,5,6-trimethoxy-1-indanone (Haworth et al., J. Chem. Soc. 1952 1583-1588), 2.16 g (10 mmole) of 1-(1-oxo-3-phenyl-2-propenyl)-piperazine, 0.92 g (11 mmole) of NaHCO_3 in 8 ml of methanol is refluxed with stirring for 16 hours. After cooling, and maintaining the temperature at 0-5°C, 0.77 g (20 mmole) of NaBH_4 are added at portions, then the mixture is allowed to stand for 4 hours at room temperature under stirring. The mixture is cooled and made acidic by the addition of 15% aqueous HCl. After concentration under reduced pressure, the mixture is made alkaline by the addition of an aqueous 5% solution of sodium carbonate and extracted with methylene dichloride. The organic phase is washed with H_2O to neutrality and dried over sodium sulfate. On evaporation under reduced pressure, 4.2 g are obtained as a mixture of diastereoisomers cis/trans which are separated by flash-chromatography through a column filled with silicagel 60 Merck 230-400 mesh, using chloroform: acetone 50:50 as the eluent. After crystallization from acetone, 1.2 g of cis-isomer are obtained (yield 27.4%), m.p. 162-163°C. On crystallization from acetone, 1.25 g of trans-isomer are obtained (yield 28.5%); m.p. 168-170°C.

Analysis for $\text{C}_{25}\text{H}_{30}\text{N}_2\text{O}_5$ %	calc.	C 68.47	H 6.89	N 6.39
<u>cis</u> -isomer	found	68.33	6.88	6.40
<u>trans</u> -isomer		68.40	6.86	6.40

EXAMPLE 5

cis and trans 2-[4-(2-oxo-2-benzimidazoliny1)-1-piperidinyl]-4,5,6-trimethoxy-1-indanol (MG 38007 and MG 38019)

A mixture of 3.3 g of 2-bromo-4,5,6-trimethoxy-1-indanone (11 mmole), 2.17 g of 4-(2-oxo-1-benzimidazoliny1)-piperidine (10

mmole), 0.92 g of NaHCO_3 (11 mmole) in 60 ml of methanol is refluxed under stirring for 5 hours, the mixture is then cooled and the precipitate is collected and washed with water, then with methanol for 30 minutes at 40°C.

Yield 3 g (68.5% of 2-[4-(2-oxo-1-benzimidazoliny1)-1-piperidinyl]-4,5,6-trimethoxy-1-indanone, m.p. 197-199°C (MG 38005).

Analysis for $\text{C}_{24}\text{H}_{27}\text{N}_3\text{O}_5$	% calc.	C	65.88	H	6.22	N	9.60
	found		65.68		6.20		9.57

To 2 g (4.6 mmole) of the foregoing intermediate in 10 ml of methanol, 0.35 g of NaBH_4 (9.2 mmole) dissolved in 1 ml of water is dropped with stirring at the boiling temperature of the solvent. Heating is then continued for additional 3 hours.

After cooling the reaction mixture is made acidic by the addition of aqueous 15% HCl , then it is concentrated under reduced pressure, the residue is treated with aqueous 5% Na_2CO_3 solution to alkaline reaction and extracted with CH_2Cl_2 . The organic phase is washed with water and dried over sodium sulfate. On evaporation under reduced pressure a mixture of cis-trans diastereoisomers is obtained which are separated by flash chromatography using $\text{CHCl}_3:\text{CH}_3\text{OH}$ 95:5 as the eluent. After crystallization from aqueous methanol 1.38 g of cis-isomer (yield 68.2%) are obtained; m.p. 238-239°C. By washing with hot acetone 0.44 g (yield 21.8%) of trans-isomer are obtained; m.p. 256-258°C.

Analysis for $\text{C}_{24}\text{H}_{28}\text{N}_3\text{O}_5$	% calc.	C	65.58	H	6.65	N	9.56
<u>cis</u> -isomer	found		65.45		6.64		9.54
<u>trans</u> -isomer			65.48		6.60		9.52

EXAMPLE 6

trans 2-(n-Octylamino)-4,5,6-trimethoxy-1-indanol (MG 38006)

Into 16 g of 4,5,6-trimethoxy-1-indanone (Haworth et al., J. Chem. Soc. 1952 1583-88) in 280 ml of anhydrous diethyl ether at the temperature of 15-20°C and with stirring, anhydrous hydrogen chloride is bubbled while simultaneously dropping into the solution 9 ml. of n-butyl nitrite. When the n-butyl nitrite addition is terminated, bubbling of HCl is continued at 5°C until precipitation is complete. The precipitate is collected and washed with diethyl ether and crystallized from ethanol. Yield 13.4 g (74%) of 2-isonitroso-4,5,6-trimethoxy-1-indanone; m.p. 203-204°C.

To a solution of 2 g of the foregoing compound in 20 ml of methanol, 4 ml of a 20% solution of HCl in ethanol are added; then the mixture is hydrogenated in the presence of 0.5 g of 5% Pd/C at room temperature and pressure. The catalyst is then filtered off and the solution is concentrated under reduced pressure. the residue is recrystallized from methanol/diethyl ether giving 1.66 g (yield 76.2%) of 2-amino-4,5,6-trimethoxy-1-indanone hydrochloride; m.p. 206-208°C (dec.)

The above obtained amino ketone hydrochloride is dissolved in 50 ml of methanol, then 2 g of NaBH₄ are added in small portions at 5°C under continuous stirring. the mixture is then allowed to stand at room temperature for 1 hour, then it is diluted with water, extracted with chloroform and the organic solution is dried over magnesium sulfate. After concentration under reduced pressure the residue is cristallized from chloroform/hexane. The product is dissolved in methanol and treated with HCl in ethanol giving 1.09 g of trans-2-amino-4,5,6-trimethoxy-1-indanol hydrochloride on addition of

diethyl ether, as a precipitate having m.p. 167°C (dec.); yield 54%. To a mixture of 4 g of the above obtained hydrochloride, 2.06 g of octanal and 150 ml of CH_3OH , 4.1 g of NaBH_3CN are gradually added at 5°C with stirring, then the mixture is allowed to stand overnight at room temperature. After this time it is cooled to 5°C, made acidic with 15% HCl , diluted with water, then made alkaline with sodium bicarbonate, extracted with chloroform and the organic extract is dried over sodium sulfate and concentrated to dryness under reduced pressure.

The crude product is purified by flash chromatography, eluent $\text{CHCl}_3:\text{CH}_3\text{OH}$ 95:5. By crystallization from acetone/hexane, 2 g of product are obtained (yield 39%), m.p. 123-124°C.

Analysis for $\text{C}_{20}\text{H}_{33}\text{NO}_4$	% calc.	C	68.34	H	9.46	N	3.98
	found		68.20		9.44		3.97

EXAMPLE 7

cis and trans 2-[4-(1-Oxo-3-phenyl-2-propenyl)-1-piperazinyl]-6,7-dimethoxy-1-tetralol (MG 38056 and MG 38035).

A mixture of 2.76 g of 2-bromo-6,7-dimethoxy-1-tetralone (Wilds., J.Am.Chem.Soc. 64 1421, 1942), 1.9 g of cinnamoylpiperazine and 0.81 g of sodium bicarbonate in 20 ml of methanol is refluxed with stirring for 6 hours. Still at the boiling temperature, 0.66 g of NaBH_4 dissolved in 3 ml of water are dropped and reflux is continued for additional 6 hours.

The mixture is then cooled, diluted with water and extracted with chloroform. From the organic extract a mixture of cis-trans diastereoisomers is obtained by evaporation of the solvent; they are

separated by flash chromatography using chloroform: acetone 70:30 as the eluent. After crystallization from aqueous ethanol, 0.97 g (26.1%) of trans-isomer, m.p. 168-170°C, and 0.94 g (25.3%) of cis-isomer, m.p. 102-104°C, are obtained.

Analysis for C ₂₅ H ₃₀ N ₂ O ₄	% calc.	C	71.06	H	7.15	N	6.63
<u>cis</u> -isomer	found		70.92		7.13		6.62
<u>trans</u> -isomer			71.01		7.12		6.65

The coupling constant was determined by ¹H NMR (300 MHz) in pyridine. For the trans-isomer it was J_{1,2}=9.7 Hz; /for the cis-isomer it was J_{1,2}=3.5 Hz/.

EXAMPLE 8

cis-and trans 2-[4-(2-Oxo-1-benzimidazoliny1)-1-piperidiny1]-6,7-dimethoxy-1-tetralol (MG 38060 and MG 38041).

A mixture of 3 g of 2-bromo-6,7-dimethoxy-1-tetralone, 2.28 g of 4-(2-oxo-1-benzimidazoliny1)-piperidine and 0.9 g of NaHCO₃ in 60 ml of methyl ethyl ketone is heated at 60°C with stirring for 7 hours under a nitrogen atmosphere, then stirring is continued overnight at room temperature. The mixture is cooled to 0°C and the precipitate is collected and washed with diethyl ether. Yield 4.2 g (94.9%, m.p. 238-239°C) of 2-[4-(2-oxo-1-benzimidazoliny1)-1-piperidiny1]-6,7-dimethoxy-1-tetralone which is used as such for the following step.

To 2.95 g of the foregoing compound dissolved in 40 ml of tetrahydrofuran (THF), 0.53 g of LiAlH₄ are gradually added under a nitrogen atmosphere. Stirring is then continued for additional 3 hours at room temperature, then the mixture is cooled and the excess hydride is destroyed with ethyl acetate and with ice. The

mixture is filtered and the filtrate is concentrated under reduced pressure. The residue is treated with chloroform, washed with water and evaporated to dryness. The distereoisomeric mixture is separated by flash chromatography using $\text{CHCl}_3:\text{CH}_3\text{OH}$ 95:5 as the eluent.

trans-isomer: yield 1.2 g (40.5%), m.p. 206-208°C







cis-isomer : yield 0.4 g (13.5%), m.p. 233-235°C.

The configuration was determined by ^1H NMR (300 MHz) in CDCl_3 . The coupling constant was $J_{1,2} = 9.7$ Hz for the trans-isomer and $J_{1,2} = 2.5$ Hz for the cis-isomer.







Analysis for $\text{C}_{24}\text{H}_{29}\text{N}_3\text{O}_4$	calc. %	C	68.05	H	6.80	N	9.92
<u>cis</u> -isomer			67.91		6.89		9.90
<u>trans</u> -isomer			66.92		6.88		9.91

The following is a complete reporte of the NMR obtained.

TRANS

δ_{H} : 10.15 (1H, br, NH); 7.30-7.00 (4H, m, ); 7.13 (1H, s, ); 6.57 (1H, s, ); 4.66 (1H, d, $J = 9.7$ Hz, ); 4.40 (1H, m, piperidinic); 3.91 and 3.86 (2x3H, s, OMe) 3.13 (1H, m, piperidinic); 2.91 (2H, m, piperidinic); 2.72 (1H, m, ); 2.65-2.20 (3H, m piperidinic); 2.10 and 1.66 (2x1H, m, ); 1.94 (2H, m, piperidinic).

CIS

δ H : 9.76 (1H, br, NH); 7.30-7.00 (4H, m, );
 6.93 (1H, s, ); 6.62 (1H, s, ); 4.77 (1H, d,  J=2.5 Hz); 4.44 (1H, m, piperidinic) 3.89 and 3.87 (2 x 3H, s, OMe); 3.50 and 3.36 (2 x 1H, m, piperidinic) 3.00-2.50 (6H, m, 4 H piperidinic + 2H ) 2.10-1.80 (4H, m, 2H piperidinic + 2H )

EXAMPLE 9

cis and trans 2-[4-(1-Oxo-3-phenyl-2-propenyl)-1-piperazinyl]-5,6,7-trimethoxy-1-tetralol (MG 38033 and MG 38025).

To a solution of 3.54 g of 5,6,7-trimethoxy-1-tetralone (Snider et al., Organic Preparations and Procedures Int., 5(6) 291-298, 1973) in 40 ml of THF under stirring and at room temperature, 5.64 g of phenyl trimethyl ammonium tribromide is gradually added in a period of 6 hours, then stirring is continued for additional 30 minutes, after which the mixture is poured into 400 ml of a 5% NaHCO₃ solution and ice, and extracted with diethyl ether. From the organic phase a residue is obtained by evaporation and is crystallized from ethanol.

Yield 4.09 g (86.5%) of 2-bromo-5,6,7-trimethoxy-1-tetralone, m.p. 107-107.5°C. This intermediate compound is used for the preparation of the title compounds by substantially the same process as described in Example 7 for the 6,7-dimethoxy analogue. Purification was effected by crystallization from acetone/hexane.

cis-isomer: yield 1.45 g (32%), m.p. 171-172°C,

trans-isomer : yield 0.95 (21%) m.p. 140-142°C.

Analysis for $C_{26}H_{32}N_2O_5$ % calc. C 69.9 H 7.13 N 6.19

cis-isomer found 68.86 7.11 6.18

trans-isomer 68.91 7.15 6.19

The configuration was determined by 1H NMR (300 MHz) in $CDCl_3$. The coupling constant was $J_{1,2} = 10.23$ Hz for the trans-isomer and 3.5 Hz for the cis-isomer.

EXAMPLE 10

trans 2-[4-(2-Oxo-1-benzimidazolidinyl)-1-piperidinyl]-5,6,7-trimethoxy-1-tetralol (MG 38028).

By substantially the same process as described in the first part of Example 8 for the 6,7-dimethoxy analogue, the intermediate 2-[4-(2-oxo-1-benzimidazolyl)-1-piperidinyl]-5,6,7-trimethoxy-1-tetralone was prepared in a 70% yield and showed m.p. 215°C (dec.). To 5 g of this intermediate dissolved in 100 ml of THF, 1.23 g of $LiAlH_4$ is gradually added under stirring under a nitrogen atmosphere at 10°C, then stirring is continued at room temperature for 5 hours.

After cooling to 0°C the excess hydride is destroyed with ethyl acetate and then with water and the mixture is filtered.

The filtrate is evaporated to dryness under reduced pressure, the residue is dissolved in chloroform and the solvent removed in vacuo. By column chromatography and elution with chloroform: acetone 60:40, the trans-isomer is obtained, m.p. 237-239°C, yield 2.5 g (49.8%).

Analysis for $C_{25}H_{31}N_2O_5$ % calc. C 66.20 H 6.89 N 9.26

found 66.07 6.88 9.24

The configuration was determined by ^1H NMR (300 MHz) in pyridine. The coupling constant was $J = 10.23$ Hz.

By procedures substantially identical to those described in the preceding disclosure and Examples the following compounds were prepared. Yields of final step and melting points are given.

EXAMPLE 11

cis-and trans-2-[4-(2-Oxo-5-chloro-1-benzimidazoliny1)-1-piperidinyl]-4,5,6-trimethoxy-1-indanol.

Prepared from 2-bromo-4,5,6-trimethoxy-1-indanone and 4-(2-oxo-5-chloro-1-benzimidazoliny1)-piperidine in the presence of NaHCO_3 and hydrogenation of the intermediate with NaBH_4 . The diastereomeric mixture was separated by flash chromatography through silica gel and elution with $\text{CHCl}_3:\text{CH}_3\text{OH}$ 95:5 mixture.

cis (MG 38119) : 39.8%; 242-244°C (dec.)

trans (MG 38122) : 13.3%; 244-246°C (dec.)

EXAMPLE 12

cis and trans-2-[4-(2-Oxo-5-chloro-1-benzimidazoliny1)-1-piperidinyl]-5,6-dimethoxy-1-indanol.

Prepared from 4-(2-oxo-5-chloro-1-benzimidazoliny1)-piperidine and 2-bromo-5,6-dimethoxy-1-indanone as described in the foregoing example. The intermediate ketone 2-[4-(2-oxo-5-chloro-1-benzimidazoliny1)-1-piperidinyl]-5,6-dimethoxy-1-indanone (MG 38120) was obtained in 70.1% yield and has m.p. 250-254°C (dec).

By hydrogenation with NaBH_4 the only cis form was isolated in 47.8% yield. Using LiAlH_4 as the hydrogenating agent a mixture of the cis and trans forms is obtained and is separated by chromatography

through silica gel. Yields were 27.9% of cis and 37.8% of trans form.

cis (MG 38121) : 279-281°C (dec.)

trans (MG 38131) : 259-261°C (dec.)

EXAMPLE 13

cis and trans 2-(4-Benzamido-1-piperidinyl)-5,6-dimethoxy-1-indanol.

Prepared from 4-benzamidopiperidine and 2-bromo-5,6-dimethoxy-1-indanone. The intermediate 2-(4-benzamido-1-piperidinyl)-5,6-dimethoxy-1-indanone (MG 38128) was obtained in 65.8% yield and showed m.p. 238-240°C (dec.). Hydrogenation is carried out with NaBH_4 .

cis (MG 38112) : 46.6%; 243-244°C (methanol)

trans (MG 38130) : 9.1%; 235-236°C (dec.)

EXAMPLE 14

cis-2-[4-(2-Methyl-1-benzimidazoliny1)-piperidinyl]-5,6-dimethoxy-1-indanol (MG 38125).

Prepared from 4-(2-methyl-1-benzimidazoliny1)-piperidine hydrochloride hydrobromide and 2-bromo-5,6-dimethoxy-1-indanone without isolation of the intermediate ketone and using NaBH_4 as the hydrogenating agent. Yield 54.7%; m.p. 255-256°C (chloroform/diethyl ether).

By procedures analogous to those of the foregoing examples the following compounds were prepared starting from the appropriate intermediates.

EXAMPLE 15

cis-2-(4-Benzamido-1-piperidinyl)-4,5,6-trimethoxy-1-indanol (MG 38107): 62.3%; 197.5-198.5°C,

EXAMPLE 16

cis-2-[4-(2-Methoxyphenyl)-1-piperazinyl]-5,6-dimethoxy-1-indanol (MG 38100): 44.7%; m.p. 192-194°C.

EXAMPLE 17

trans-2-[4-(2-Methoxyphenyl)-1-piperazinyl]-4,5,6-trimethoxy-1-indanol (MG 38099) : 29.8%; 167-168°C (ethanol).

EXAMPLE 18:

2-[4-(2-Methyl-1-benzimidazoliny1)-1-piperidinyl]-4,5,6-trimethoxy-1-indanol.

cis (MG 38129); 42.8%; 198-200°C (isopropanol)

trans (MG 38133) ; 17.2% 151-153°C (ethanol).

EXAMPLE 19

cis and trans-2-[4(2-Oxo-5-chloro-1-benzimidazoliny1)-1-piperidinyl]-5,6,7- trimethoxy-1-tetralol.

cis (MG 16489) 10%; 124-126°C (CHCl₃/petroleum ether)

trans (MG 16456) 40%; 222-224°C (isopropanol)

The intermediate ketone, 2-[4-(2-oxo-5-chloro-1-benzimidazoliny1)-1-piperidinyl]-5,6,7-trimethoxy-1-tetralone (MG 16459) showed m.p. 205-209°C (methyl ethyl ketone).

EXAMPLE 20

2-[4-(2-Oxo-1-benzimidazoliny1)-1-piperilidenyl]-4,5,6-trimethoxy-1-indanone (MG 38114) : 25.3%, 174-177°C (dec.).

EXAMPLE 21

cis-2-[4-(2-Oxo-1-benzimidazoliny1)-methyl-1-piperidiny1]-4,5,6-trimethoxy-1-indanol (MG 38142): 30.3%, 224-226°C (ethanol).

EXAMPLE 22

2-[4-(2-Oxo-1-benzimidazoliny1)-1-piperilideny1]-5,6-dimethoxy-1-indanone-(MG 38136): 47.3%; 224-226°C (DMF/H₂O).

EXAMPLE 23

cis-2-[4-(2-Oxo-1-benzimidazoliny1)-methyl-1-piperidiny1]-5,6-dimethoxy-1-indanol (MG 38140): 47.4%; 236-238°C (CHCl₃/ethyl ether).

EXAMPLE 24

2-[4-(2-Methyl-1-benzimidazoliny1)-1-piperidiny1]-5,6,7-trimethoxy-1-tetralol.

cis (MG 16490): 15%; 100-104°C (dec.)

trans (MG 16478): 26%; 100-105°C (dec.)


The NMR spectra confirm the structure.

EXAMPLE 25



trans-2-(4-Benzamido-1-piperidiny1)-5,6,7-trimethoxy-1-tetralol (MG 16480): 15%; 190-192°C.

Rc1cc(R1)c(R2)c(cc12)C(O)C(R3)R4


R₃ represents hydrogen and R₄ represents an alkyl group; or alternatively R₃ and R₄ taken together represent a divalent group selected from



b)


*NC(=O)c1ccccc1

and




wherein R_4 represents a lower alkyl group;

c)




and

d)




wherein W represents hydrogen, phenyl, alkoxyphenyl, 2-furoyl, nicotinoyl radical or a radical




in which Z represents 2-thienyl or phenyl optionally substituted with 1-3 halogen or alkoxy groups; and its salts with inorganic acids, organic acids, cationic exchange resins and complexes with cyclodextrins.

2.- A compound of the formula



in its cis and trans configuration and mixtures thereof, wherein R, R₁, R₂, R₃ and R₄ have the same significance as in claim 1, and its salts with inorganic and organic acids.

3.- A compound of the formula



in its cis and trans configuration and mixtures thereof, wherein R, R₁, R₂, R₃ and R₄ have the same significance as in claim 1, and its salts with inorganic and organic acids.

4.- A compound selected from the racemate and the cis and the trans stereoisomeric forms of 2-[4-(2-oxo-1-benzimidazoliny1)-1-piperidinyl]-5,6-dimethoxy-1-indanol.

5. A compound selected from the racemate and the cis and trans stereoisomeric forms of 2-[4-(2-oxo-1-benzimidazoliny1)-1-piperidinyl]-4,5,6-trimethoxy-1-indanol.

6.- A compound selected from the racemate and the cis and the trans stereoisomeric forms of 2-[4-(1-oxo-3-phenyl-2-propenyl)-1-piperazinyl]-5,6-dimethoxy-1-indanol.


7.- A compound selected from the racemate and the cis and the trans stereoisomeric forms of 2-[4-(2-oxo-1-benzimidazoliny1)-1-piperidinyl]-6,7-dimethoxy-1-tetralol.

8. A compound selected from the racemate and the cis and the trans stereoisomeric forms of 2-(4-benzamido-1-piperidinyl)-5,6-dimethoxy-1-indanol.

9. A compound selected from the racemate and the cis and the trans stereoisomeric forms of 2-(4-benzamido-1-piperidinyl)-4,5,6-trimethoxy-1-indanol.

10. A compound selected from the racemate and the cis and the trans stereoisomeric forms of 2-[4-(2-oxo-5-chloro-1-benzimidazoliny1)-1-piperidinyl]-5,6-dimethoxy-1-indanol.

11. A compound of the formula:




wherein n represents an integer selected from 1 and 2;

R , R_1 and R_2 represent hydrogen or a lower alkoxy group, with the proviso that at least two alkoxy groups are present; or two adjacent radicals selected from $R+R_1$ and R_1+R_2 represent an alkylene-dioxy group;


R_3 represents hydrogen and R_4 represents an alkyl group, or alternatively R_3 and R_4 taken together represent a divalent group selected from

a)




wherein Y represents hydrogen or halogen;

b)




wherein A is a group selected from



39


wherein R_4 represents a lower alkyl group;

c)



and

d)




wherein W represents hydrogen, phenyl, alkoxyphenyl, 2-furoyl, nicotinoyl radical or a radical



in which Z represents 2-thienyl or phenyl optionally substituted with 1-3 halogen or alkoxy groups.

12. A process for preparing a compound of the formula




wherein n represents an integer selected from 1 and 2;

R , R_1 and R_2 represent hydrogen or a lower alkoxy group, with the proviso that at least two alkoxy groups are present; or two adjacent radicals selected from $R+R_1$ and R_1+R_2 represents an alkylene-dioxy group;

R_3 represents hydrogen and R_4 represents an alkyl group; or alternatively R_3 and R_4 taken together represent a divalent group selected from


Chemical structure of a benzimidazole derivative. The structure shows a benzimidazole ring system. The nitrogen at position 2 is substituted with a $-\text{CH}_2-\text{CH}_2-$ group, which is further connected to another $-\text{CH}_2-\text{CH}_2-$ group. The nitrogen at position 1 is substituted with a $-\text{CH}_2-\text{CH}_2-$ group. The benzene ring is labeled with a 'Y' at the 6-position.

b)




*C(=O)c1ccccc1 , O=C1NC2=CC=CC=C2N1 and *C1=NC2=CC=CC=C2N1

c)




d)



$$-\text{CO}-\text{CH}=\text{CH}-\text{Z}$$

in which Z represent 2-thienyl or phenyl optionally substituted with 1-3 halogen or alkoxy groups which comprises contacting a

haloketone of the formula




with a secondary amine of the formula HNR_3R_4 , wherein R , R_1 , R_2 , R_3 , R_4 and n have the same significance as in claim 1, in the presence of a proton acceptor and optionally in the presence of an inert solvent, and hydrogenating the obtained aminoketone of the formula




by conventional procedures.

13. A process for preparing a compound of the formula



which comprises contacting an amino alcohol of the formula



wherein R , R_1 , R_2 , R_3 , R_4 and n have the same significance as in claim 1, with an aldehyde of the formula OHC-X wherein X represents

a linear or branched alkyl radical at a temperature between 0°C and 20°C in an inert organic solvent, while adding to the reaction mixture a hydrogenating agent selected from metal hydrides metal double hydrides, metal double cyano hydrides and hydrogen in the presence of a catalyst.


14. A process according to claim 11, wherein the hydrogenating agent is sodium boron cyano hydride.

15. A process according to claim 11, wherein the hydrogenating agent is lithium boron cyano hydride.

AMENDED CLAIMS

[received by the International Bureau on 20 March 1987 (20.03.87)
original claims 1,2,3,11,12 and 13 replaced by amended claims;
other claims unchanged. (8 pages)]

1.- A compound of the formula




in its cis and trans configuration and mixtures thereof, wherein

n represents an integer selected from 1 and 2;


R , R_1 and R_2 represent hydrogen or a lower alkoxy group, with the proviso that at least two alkoxy groups are present; or two adjacent radicals selected from $R+R_1$ and R_1+R_2 represent an alkylendioxy group; R_3 represents a divalent group selected from

a)




wherein Y represents hydrogen or halogen;

b)




wherein A is a group selected from




wherein R_4 represents a lower alkyl group;

c)




and

d)




wherein W represents hydrogen, phenyl, alkoxyphenyl, 2-furoyl, nicotinoyl radical or a radical




in which Z represents 2-thienyl or phenyl optionally substituted with 1-3 halogen or alkoxy groups; and its salts with inorganic acids, organic acids, cationic exchange resins and complexes with cyclodextrins.

2.- A compound of the formula



in its cis and trans configuration and mixtures thereof, wherein R, R₁, R₂, R₃ have the same significance as in claim 1, and its salts with inorganic and organic acids.

3.- A compound of the formula



in its cis and trans configuration and mixtures thereof, wherein R, R₁, R₂, R₃ have the same significance as in claim 1, and its salts with inorganic and organic acids.

4.- A compound selected from the racemate and the cis and the trans stereoisomeric forms of 2-[4-(2-oxo-1-benzimidazoliny1)-1-piperidinyl]-5,6-dimethoxy-1-indanol.

5. A compound selected from the racemate and the cis and trans stereoisomeric forms of 2-[4-(2-oxo-1-benzimidazoliny1)-1-piperidinyl]-4,5,6-trimethoxy-1-indanol.

6.- A compound selected from the racemate and the cis and the trans stereoisomeric forms of 2-[4-(1-oxo-3-phenyl-2-propenyl)-1-piperazinyl]-5,6-dimethoxy-1-indanol.


7.- A compound selected from the racemate and the cis and the trans stereoisomeric forms of 2-[4-(2-oxo-1-benzimidazoliny1)-1-piperidinyl]-6,7-dimethoxy-1-tetralol.

8. A compound selected from the racemate and the cis and the trans stereoisomeric forms of 2-(4-benzamido-1-piperidinyl)-5,6-dimethoxy-1-indanol.

9. A compound selected from the racemate and the cis and the trans stereoisomeric forms of 2-(4-benzamido-1-piperidinyl)-4,5,6-trimethoxy-1-indanol.

10. A compound selected from the racemate and the cis and the trans stereoisomeric forms of 2-[4-(2-oxo-5-chloro-1-benzimidazoliny1)-1-piperidinyl]-5,6-dimethoxy-1-indanol.


11. A compound of the formula:



wherein n represents an integer selected from 1 and 2;


R, R₁ and R₂ represent hydrogen or a lower alkoxy group, with the proviso that at least two alkoxy groups are present; or two adjacent radicals selected from R+R₁ and R₁+R₂ represent an alkylene-dioxy group; R₃ represents a divalent group selected from

a)




wherein Y represents hydrogen or halogen;

b)




wherein A is a group selected from




wherein R_4 represents a lower alkyl group;

c)




and

d)




wherein W represents hydrogen, phenyl, alkoxyphenyl, 2-furoyl, nicotinoyl radical or a radical



in which Z represents 2-thienyl or phenyl optionally substituted with 1-3 halogen or alkoxy groups.


12. A process for preparing a compound of the formula



wherein n represents an integer selected from 1 and 2;


R , R_1 and R_2 represent hydrogen or a lower alkoxy group, with the proviso that at least two alkoxy groups are present; or two adjacent radicals selected from $R+R_1$ and R_1+R_2 represents an alkylene-dioxy group; R_3 represents a divalent group selected from

a)




wherein Y represent hydrogen or halogen;

b)




wherein A is a group selected from




wherein R_4 represents a lower alkyl group;

c)




and

d)




wherein W represents hydrogen, phenyl, methylphenyl, alkoxyphenyl, 2-furoyl, nicotinoyl radical or a radical




in which Z represent 2-thienyl or phenyl optionally substituted with 1-3 halogen or alkoxy groups which comprises contacting a

haloketone of the formula




with a secondary amine of the formula HNR_3 , wherein R , R_1 , R_2 , R_3 and n have the same significance as in claim 1, in the presence of a proton acceptor and optionally in the presence of an inert solvent, and hydrogenating the obtained aminoketone of the formula




by conventional procedures.

13. A process for preparing a compound of the formula



which comprises contacting an amino alcohol of the formula



wherein R , R_1 , R_2 , R_3 and n have the same significance as in claim 1, with an aldehyde of the formula OHC-X wherein X represents

a linear or branched alkyl radical at a temperature between 0°C and 20°C in an inert organic solvent, while adding to the reaction mixture a hydrogenating agent selected from metal hydrides metal double hydrides, metal double cyano hydrides and hydrogen in the presence of a catalyst.

14. A process according to claim 11, wherein the hydrogenating agent is sodium boron cyano hydride.

15. A process according to claim 11, wherein the hydrogenating agent is lithium boron cyano hydride.

STATEMENT UNDER ARTICLE 19

All amendments substantially relate to the elimination of the symbol " R_4 " from all formulas where it was present and from the definitions relating to said formulas.

Reason for that is the intervened lack of interest by the applicant in compounds in which the nitrogen of the generic formulas is not a member of an heterocyclic ring.

This removes also a mistake made in original claims 1, 11 and 12, where the symbol " R_4 " occurred twice with different meanings.

INTERNATIONAL SEARCH REPORT

International Application No PCT/EP 86/00606

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) * According to International Patent Classification (IPC) or to both National Classification and IPC 4 C 07 C 93/14; C 07 D 295/08; 295/18; 211/58; 401/04; IPC : C 07 C 97/10/(C 07 D 401/04, 235:25, 211:58, C 07 D 401/04, ./.																										
II. FIELDS SEARCHED <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black;">Minimum Documentation Searched 7</div> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 30%; border-bottom: 1px solid black;">Classification System</th> <th style="border-bottom: 1px solid black;">Classification Symbols</th> </tr> <tr> <td style="border-right: 1px solid black; padding: 5px; vertical-align: top;">IPC⁴</td> <td style="padding: 5px; vertical-align: top;">C 07 C 93/00; C 07 D 211/00; C 07 D 295/00; C 07 D 401/00; A 61 K 31/00</td> </tr> </table> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black;">Documentation Searched other than Minimum Documentation to the extent that such documents are included in the fields searched 8</div>			Classification System	Classification Symbols	IPC ⁴	C 07 C 93/00; C 07 D 211/00; C 07 D 295/00; C 07 D 401/00; A 61 K 31/00																				
Classification System	Classification Symbols																									
IPC ⁴	C 07 C 93/00; C 07 D 211/00; C 07 D 295/00; C 07 D 401/00; A 61 K 31/00																									
III. DOCUMENTS CONSIDERED TO BE RELEVANT * <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 10%; text-align: left;">Category *</th> <th style="width: 60%; text-align: left;">Citation of Document, 11 with indication, where appropriate, of the relevant passages 12</th> <th style="width: 30%; text-align: left;">Relevant to Claim No. 13</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">X</td> <td>US, A, 2549685 (R.V. HEINZELMANN) 17 April 1951, see column 1, lines 6-53</td> <td style="text-align: center;">1</td> </tr> <tr> <td style="text-align: center;">X</td> <td>Journal of Chemical Society C, 1967 (US) R.I. Thrift: "Derivatives of 2-aminotetralin", pages 288-293, see pages 289, 290, 292</td> <td style="text-align: center;">1</td> </tr> <tr> <td style="text-align: center;">X</td> <td>US, A, 4533745 (D.E. MCCLURE) 6 August 1985, see columns 1, 2</td> <td style="text-align: center;">1, 12</td> </tr> <tr> <td style="text-align: center;">X</td> <td>EP, A, 0000395 (SANDOZ) 24 January 1979, see claims; page 10, lines 12-28</td> <td style="text-align: center;">1</td> </tr> <tr> <td style="text-align: center;">Y</td> <td>FR, A, 2323388 (SQUIBB) 8 April 1977, see claims</td> <td style="text-align: center;">1</td> </tr> <tr> <td style="text-align: center;">Y</td> <td>FR, A, 1360532 (JANSSEN) 31 March 1964, see abstract</td> <td style="text-align: center;">1</td> </tr> <tr> <td style="text-align: center;">Y</td> <td>GB, A, 2008106 (MITSUBISHI YUKA PHARMACEUTICAL) 31 May 1979, see claims</td> <td style="text-align: center;">1</td> </tr> </tbody> </table>			Category *	Citation of Document, 11 with indication, where appropriate, of the relevant passages 12	Relevant to Claim No. 13	X	US, A, 2549685 (R.V. HEINZELMANN) 17 April 1951, see column 1, lines 6-53	1	X	Journal of Chemical Society C, 1967 (US) R.I. Thrift: "Derivatives of 2-aminotetralin", pages 288-293, see pages 289, 290, 292	1	X	US, A, 4533745 (D.E. MCCLURE) 6 August 1985, see columns 1, 2	1, 12	X	EP, A, 0000395 (SANDOZ) 24 January 1979, see claims; page 10, lines 12-28	1	Y	FR, A, 2323388 (SQUIBB) 8 April 1977, see claims	1	Y	FR, A, 1360532 (JANSSEN) 31 March 1964, see abstract	1	Y	GB, A, 2008106 (MITSUBISHI YUKA PHARMACEUTICAL) 31 May 1979, see claims	1
Category *	Citation of Document, 11 with indication, where appropriate, of the relevant passages 12	Relevant to Claim No. 13																								
X	US, A, 2549685 (R.V. HEINZELMANN) 17 April 1951, see column 1, lines 6-53	1																								
X	Journal of Chemical Society C, 1967 (US) R.I. Thrift: "Derivatives of 2-aminotetralin", pages 288-293, see pages 289, 290, 292	1																								
X	US, A, 4533745 (D.E. MCCLURE) 6 August 1985, see columns 1, 2	1, 12																								
X	EP, A, 0000395 (SANDOZ) 24 January 1979, see claims; page 10, lines 12-28	1																								
Y	FR, A, 2323388 (SQUIBB) 8 April 1977, see claims	1																								
Y	FR, A, 1360532 (JANSSEN) 31 March 1964, see abstract	1																								
Y	GB, A, 2008106 (MITSUBISHI YUKA PHARMACEUTICAL) 31 May 1979, see claims	1																								
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>* Special categories of cited documents: 10</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>																										
IV. CERTIFICATION <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; border-bottom: 1px solid black;">Date of the Actual Completion of the International Search</td> <td style="width: 50%; border-bottom: 1px solid black;">Date of Mailing of this International Search Report</td> </tr> <tr> <td style="text-align: center;">29th January 1987</td> <td style="text-align: center;">20 FEB. 1987</td> </tr> <tr> <td style="border-bottom: 1px solid black;">International Searching Authority</td> <td style="border-bottom: 1px solid black;">Signature of Authorized Officer</td> </tr> <tr> <td style="text-align: center;">EUROPEAN PATENT OFFICE</td> <td style="text-align: center;">M. VAN MOL </td> </tr> </table>			Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	29th January 1987	20 FEB. 1987	International Searching Authority	Signature of Authorized Officer	EUROPEAN PATENT OFFICE	M. VAN MOL																
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report																									
29th January 1987	20 FEB. 1987																									
International Searching Authority	Signature of Authorized Officer																									
EUROPEAN PATENT OFFICE	M. VAN MOL																									

INTERNATIONAL SEARCH REPORT

International Application No PCT/EP 86/00606

-2-

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC IPC ⁴ : 235:08,211:58)														
II. FIELDS SEARCHED <div style="text-align: right; font-size: small;">Minimum Documentation Searched ⁷</div> <table style="width: 100%; border: none;"> <tr> <td style="width: 30%; border-bottom: 1px solid black; font-size: small;">Classification System</td> <td style="border-bottom: 1px solid black; font-size: small;">Classification Symbols</td> </tr> <tr> <td style="height: 40px; vertical-align: top; padding-top: 5px;">IPC ⁴</td> <td></td> </tr> </table> <div style="text-align: center; font-size: x-small; margin-top: 10px;"> Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸ </div>			Classification System	Classification Symbols	IPC ⁴									
Classification System	Classification Symbols													
IPC ⁴														
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹ <table style="width: 100%; border: none;"> <tr> <th style="width: 10%; font-size: x-small; text-align: left;">Category ⁹</th> <th style="width: 70%; font-size: x-small; text-align: left;">Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²</th> <th style="width: 20%; font-size: x-small; text-align: left;">Relevant to Claim No. ¹³</th> </tr> <tr> <td style="vertical-align: top; padding: 5px;">X</td> <td style="vertical-align: top; padding: 5px;"> European Journal of Medicinal Chemistry, volume 18, no. 3, 1983 Chatenay-Malabry (FR) J.G. Cannon: "Demi-rigid ketone congeners of catecholemines", pages 291-292, see page 291 -- </td> <td style="vertical-align: top; text-align: center; padding: 5px;">11</td> </tr> <tr> <td style="vertical-align: top; padding: 5px;">X</td> <td style="vertical-align: top; padding: 5px;"> Chemical Abstracts, volume 85, no. 9, 30 August 1976, Columbus, Ohio (US) see page 542, abstract 62844s & JP, A, 75151853 (TAKEDA CHEMICAL INDUSTRIES, LTD) 6 December 1975 -- </td> <td style="vertical-align: top; text-align: center; padding: 5px;">11,12</td> </tr> <tr> <td style="vertical-align: top; padding: 5px;">X</td> <td style="vertical-align: top; padding: 5px;"> GB, A, 1429028 (TAKEDA) 24 March 1976, see claims; examples ----- </td> <td style="vertical-align: top; text-align: center; padding: 5px;">11,12</td> </tr> </table>			Category ⁹	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	X	European Journal of Medicinal Chemistry, volume 18, no. 3, 1983 Chatenay-Malabry (FR) J.G. Cannon: "Demi-rigid ketone congeners of catecholemines", pages 291-292, see page 291 --	11	X	Chemical Abstracts, volume 85, no. 9, 30 August 1976, Columbus, Ohio (US) see page 542, abstract 62844s & JP, A, 75151853 (TAKEDA CHEMICAL INDUSTRIES, LTD) 6 December 1975 --	11,12	X	GB, A, 1429028 (TAKEDA) 24 March 1976, see claims; examples -----	11,12
Category ⁹	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³												
X	European Journal of Medicinal Chemistry, volume 18, no. 3, 1983 Chatenay-Malabry (FR) J.G. Cannon: "Demi-rigid ketone congeners of catecholemines", pages 291-292, see page 291 --	11												
X	Chemical Abstracts, volume 85, no. 9, 30 August 1976, Columbus, Ohio (US) see page 542, abstract 62844s & JP, A, 75151853 (TAKEDA CHEMICAL INDUSTRIES, LTD) 6 December 1975 --	11,12												
X	GB, A, 1429028 (TAKEDA) 24 March 1976, see claims; examples -----	11,12												
<div style="display: flex; justify-content: space-between; font-size: x-small;"> <div style="width: 45%;"> <p>* Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>														
IV. CERTIFICATION <table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border-bottom: 1px solid black; font-size: x-small;">Date of the Actual Completion of the International Search</td> <td style="width: 50%; border-bottom: 1px solid black; font-size: x-small;">Date of Mailing of this International Search Report</td> </tr> <tr> <td style="border-bottom: 1px solid black; font-size: x-small;">International Searching Authority</td> <td style="border-bottom: 1px solid black; font-size: x-small;">Signature of Authorized Officer</td> </tr> <tr> <td style="text-align: center; padding-top: 10px;">EUROPEAN PATENT OFFICE</td> <td style="text-align: center; padding-top: 10px;">20 FEB. 1987</td> </tr> </table>			Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	International Searching Authority	Signature of Authorized Officer	EUROPEAN PATENT OFFICE	20 FEB. 1987						
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report													
International Searching Authority	Signature of Authorized Officer													
EUROPEAN PATENT OFFICE	20 FEB. 1987													

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON

INTERNATIONAL APPLICATION NO.

PCT/EP 86/00606 (SA 15026)

This Annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 10/02/87

The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A- 2549685		None	
US-A- 4533745	06/08/85	None	
EP-A- 0000395	24/01/79	JP-A- 54022383	20/02/79
		AU-A- 3808678	17/01/80
		US-A- 4308266	29/12/81
		AU-B- 521642	22/04/82
		CA-A- 1131641	14/09/82
		AT-B- 371115	10/06/83
		AT-B- 371116	10/06/83
FR-A- 2323388	08/04/77	DE-A- 2641499	31/03/77
		US-A- 4018773	19/04/77
		US-A- 4081444	28/03/78
		JP-A- 52036674	22/03/77
		GB-A- 1564527	10/04/80
FR-A- 1360532		DE-A- 1470124	08/05/69
		DE-A- 1795844	21/10/76
		FR-M- 3695	
		CH-A- 450437	
		BE-A- 633495	
		FR-M- 3042	
		US-A- 3196157	
GB-A- 2008106	31/05/79	BE-A- 871821	07/05/79
		NL-A- 7811050	10/05/79
		FR-A- 2407928	01/06/79
		DE-A- 2848263	10/05/79
		JP-A- 54066691	29/05/79
		US-A- 4189484	19/02/80
		SE-A- 7811492	09/05/79
GB-A- 1429028	24/03/76	NL-A- 7317339	20/06/74
		FR-A,B 2210603	12/07/74
		DE-A,C 2362535	20/06/74
		BE-A- 815997	30/09/74
		AU-A- 6359373	19/06/75
		AU-B- 476792	07/10/76

For more details about this annex :
see Official Journal of the European Patent Office, No. 12/82

INTERNATIONAL APPLICATION NO.
-----PCT/EP 86/00606 (SA 15026)

US-A-	4041079	09/08/77
CH-A-	590819	31/08/77
CA-A-	1022177	06/12/77
JP-A-	49082653	08/08/74

For more details about this annex :
see Official Journal of the European Patent Office, No. 12/82